Adverum Biotechnologies reports Q4 EPS (33c), consensus (36c)

Cash, cash equivalents and short-term investments were $185.6M as of December 31, 2022, compared to $203.3M as of September 30, 2022, and $305.2M as of December 31, 2021. Adverum expects cash, cash equivalents and short-term investments to fund operations into 2025.